Financial Data and Key Metrics Changes - For 2025, the company reported an Adjusted EBITDA loss of $161.3 million, with a normalized Adjusted EBITDA loss of $149.1 million, reflecting a $44 million improvement over 2024 [14][17] - Total revenue for Q4 2025 was $384.8 million, up from $370.7 million in Q4 2024, while full-year revenue was $1.46 billion, down from $1.50 billion in 2024 [14][15] - Capitated revenue per member per month (PMPM) improved by 9% to $1,060 in Q4 2025 and by 5% to $1,026 for the full year [14][15] Business Line Data and Key Metrics Changes - The medical margin for Q4 2025 was -$28.7 million, compared to $7.3 million in Q4 2024, while the full-year medical margin was $23.5 million, down from $85.4 million in 2024 [15][16] - The company achieved Four-Star status across 70% of its priority Medicare Advantage plans, indicating improved quality performance [8] Market Data and Key Metrics Changes - The company announced a partnership that expands its presence into a new Medicare Advantage geography, adding 29,000 new members, which represents a 25% year-over-year growth [9] - Total lives under management in 2026 are expected to reach approximately 140,000 members, contributing roughly $27 million in revenue [9] Company Strategy and Development Direction - The company is focused on smart growth, entering new geographies through a phased glide path to risk, which allows for operational execution before assuming full risk [9][10] - Structural and operational improvement opportunities totaling $170 million have been identified, with 75% expected from contracting and revenue-related actions [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a midpoint Adjusted EBITDA of $10 million for 2026, representing a significant improvement from 2025 [5][18] - The company aims to continue improving its cost structure while targeting investments in frontline operations to support clinical performance and medical cost stability [20] Other Important Information - The company ended 2025 with $25 million in cash and is focused on disciplined working capital management [18] - The company has made strides in improving its underlying cost structure and is committed to maintaining a disciplined operating approach [20] Q&A Session Summary Question: Are the 29,000 lives from the Nebraska agreement included in the risk member guidance midpoint of 112,000? - The 29,000 lives are additional and not included in the 112,000 full risk members [25] Question: What kind of standup costs or geo-entry costs are needed for the new geography? - The deal's economics allow for funding to cover stand-up costs, utilizing existing infrastructure [26] Question: How much of the $170 million improvement is run-rated entering the year versus what still needs to be activated in 2026? - About 75% of the $170 million is run-rated starting in January, focusing on revenue and contract updates [28] Question: How will the company interact with the Nebraska plan for the first two years? - There is a two-year glide path to risk, with a contractually set transition to full risk in 2028 [35][36] Question: What tangible examples differentiate the 2026 contracts from 2025? - Changes include adjustments in premium amounts and charges, as well as improvements in Stars performance impacting plan revenue [38][39]

Financial Data and Key Metrics Changes - Cash equivalents and marketable securities increased to $49.7 million as of December 31, 2025, from $27.6 million at year-end 2024, reflecting a $60.3 million private placement and an upfront license payment from Chugai [12][13] - Contract revenue for Q4 2025 was $1.5 million, with total revenue for the year at $1.6 million, compared to $1 million for the same period in 2024 [14][15] - Net losses for Q4 2025 were $9.1 million, down from $15.7 million in Q4 2024, and for the full year, losses were $41 million compared to $56.6 million in 2024 [16][17] Business Line Data and Key Metrics Changes - Research and development expenses decreased to $4.9 million for Q4 2025 and $20.2 million for the full year, down from $6.8 million and $26.7 million in 2024, respectively, due to cost containment measures [15][16] - General and administrative expenses for Q4 2025 were $5.1 million, down from $5.5 million in Q4 2024, and for the full year, they were $19.7 million compared to $23.9 million in 2024 [16] Market Data and Key Metrics Changes - The collaboration with Chugai Pharmaceutical has a potential total value of up to approximately $1.1 billion, highlighting the scalability of the RaniPill platform across multiple therapeutic areas [6][7] - The RaniPill platform aims to transform the delivery of biologics, particularly in the obesity treatment landscape, where current therapies face tolerability challenges [8][11] Company Strategy and Development Direction - The company is focused on advancing the RaniPill platform for oral delivery of biologics, with significant progress in strategic partnerships and financial stability [4][11] - The partnership with Chugai is expected to expand to additional drug targets, emphasizing the platform's broad applicability in high-value therapeutic areas [7][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of the RaniPill platform to transform biologic medicine delivery and highlighted the importance of ongoing clinical trials [11][18] - The company is well-capitalized to execute its development plans and advance its clinical pipeline, with a focus on obesity therapies [18] Other Important Information - The company has no outstanding debt obligations as of December 31, 2025, following the repayment of all debt due to Avenue Capital [14] - The RaniPill platform has shown promising preclinical data, with RT-114 demonstrating 111% relative bioavailability compared to subcutaneous PG-102 [8][9] Q&A Session Summary Question: Will weight loss data be presented for RT-114? - Management confirmed that weight loss is one of the endpoints in the phase I-B study, and they will compare it to historical data for PG-102 [20][21] Question: What additional doses will be explored for RT-114? - Management indicated that they will focus on tolerability and may consider higher doses if data supports it, prioritizing patient experience over maximizing weight loss [21][22] Question: What is the importance of the phase I study for RT-114? - Management highlighted that this is the first pharmacodynamics study with the RaniPill in humans, which could unlock additional value for the platform across various therapeutic areas [28][29]

Financial Data and Key Metrics Changes - For the fourth quarter of 2025, total revenue was $3.9 million, reflecting a 13% growth compared to the fourth quarter of 2024, driven by an increase in the number of CapsoCam Plus capsules sold [18] - Gross profit was $2 million, an increase of $200,000 or 13% compared to the fourth quarter of 2024, with a gross margin of 50% for the quarter [18] - Operating expenses were $9.4 million, a $3.1 million increase from the fourth quarter of 2024, primarily due to development expenses and public company costs [18] Business Line Data and Key Metrics Changes - CapsoCam Plus saw approximately 9,400 patients utilizing the system in the fourth quarter, compared to approximately 8,374 in the prior year period, representing year-over-year growth of 12% [13] - New account growth increased 16% year-over-year, reflecting continued physician adoption of CapsoCam Plus for small bowel screening [15] - The number of hospital system customers increased 87% in the fourth quarter compared to the same period last year [17] Market Data and Key Metrics Changes - As of December 31, 2025, more than 161,000 patients have been imaged using CapsoCam Plus [4] - The company is expanding its international presence, including a dedicated team in Germany and partnerships in high potential markets [15] Company Strategy and Development Direction - The long-term vision is to deliver an ingestible capsule capable of screening for multiple cancers in a single non-invasive procedure powered by advanced imaging and AI [4] - The company is focusing on advancing its AI-enabled roadmap and has submitted a 510(k) application for an AI-assisted reading module [7] - CapsoCam Colon Gen 2 is being prioritized for development, with a focus on improved imaging performance and enhanced AI functionality [8] Management's Comments on Operating Environment and Future Outlook - Management believes the company is well-positioned heading into 2026 with a growing commercial base and a differentiated AI-enabled platform [12] - The company is entering a highly competitive phase of execution, with continued commercial momentum and a disciplined pipeline strategy [20] - The additional capital raised during the quarter provides flexibility to invest in product innovation and clinical development [19] Other Important Information - The company completed a $14 million private placement with participation from both new and existing investors, reflecting continued confidence in its strategy [11] - The company is initiating a clinical study for pancreatic cancer detection, expected to begin in the second quarter of 2026 [10] Q&A Session Summary Question: Feedback on Gen 2 CapsoCam Colon efforts - Management reported that enrollment is going well, with no delays anticipated for the FDA submission by the end of Q3 [25] Question: Criteria for breakthrough designation application for pancreatic cancer detection - Management discussed the development of a scoring system for diagnostic purposes, which will be crucial for FDA application [27] Question: Development timeline for CapsoCam Colon Gen 2 - Management indicated that they expect FDA clearance within six months after submission, targeting Q1 2027 for commercial availability [37]

Financial Data and Key Metrics Changes - For Q4 2025, the company generated total revenues of $2.8 million, with net product revenues of $2.5 million from ZUNVEYL, and total revenues for the full year reached $10.2 million, including $6.8 million from ZUNVEYL [8][17] - Operating expenses for Q4 were $10.7 million, compared to $2.7 million in Q4 2024, leading to an operating loss of $7.9 million for the quarter, up from $2.7 million year-over-year [18][19] - The net loss for Q4 2025 was $6.9 million, or $0.30 per share, compared to a net loss of $5.8 million, or $0.52 per share in the same period last year [19][20] Business Line Data and Key Metrics Changes - ZUNVEYL's sales growth continued, with 4,941 bottles dispensed in Q4, marking a 62% quarter-over-quarter growth, and December alone saw 1,859 bottles dispensed, the strongest month since launch [22] - The number of prescribing doctors increased by 50% compared to Q3, and cumulative homes with prescriptions rose by 69% in Q4, indicating expanding adoption [10][22] Market Data and Key Metrics Changes - The company has signed contracts with two of the four major pharmacy benefit managers (PBMs), enhancing payer access and coverage for ZUNVEYL [10][11] - The long-term care market for Alzheimer's treatment is valued at $2 billion, and the company is focused on expanding its presence in this high-volume market [6][10] Company Strategy and Development Direction - The company aims to achieve operational profitability by 2027, supported by ongoing investments in commercial infrastructure and payer engagement strategies [7][29] - The focus for 2026 includes expanding penetration per home, deepening prescriber relationships, and accelerating payer pull-through [26][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ZUNVEYL's market positioning, citing strong prescriber feedback and the potential for increased adoption as payer access improves [17][29] - The company anticipates continued sequential growth in ZUNVEYL sales through 2026, driven by increased physician awareness and expanded payer access [21] Other Important Information - The company raised $40 million in Q3 2025, which has been allocated to expand the sales force and enhance marketing efforts [7][16] - Three real-world studies are set to be initiated in 2026 to provide further evidence of ZUNVEYL's efficacy and tolerability [7][12] Q&A Session Summary Question: Timing for conversion of additional payers and promotion into neurologist prescriber base - Management expects to see some acceleration in Q2 for regional plans, with significant pickup in Q3, and plans to expand into neurology as they approach profitability in 2027 [31][33] Question: Key takeaways from the CONVERGE study - The study will evaluate polypharmacy in long-term care and is expected to provide data on adherence, tolerability, and dosing, which will be crucial for positioning ZUNVEYL with health plans [35][36] Question: Clinical development timeline for the sublingual formulation - A PK comparative study is set to initiate, and if successful, the sublingual formulation could enter the clinic in early 2027 [40][41] Question: Sales rep expansion and inflection points - The sales force expansion is complete, and management believes this will significantly accelerate business growth [53][54] Question: Changes in marketing strategy towards psychiatry customers - The company has shifted its messaging to emphasize behavioral benefits alongside tolerability, which has broadened its prescriber base [61][63] Question: Aspirational outlook for the BEACON study - The BEACON study aims to demonstrate strong cognitive effects and tolerability for ZUNVEYL, which is crucial for market positioning [65][66]

Financial Data and Key Metrics Changes - Cash equivalents and marketable securities increased to $49.7 million as of December 31, 2025, compared to $27.6 million at year-end 2024, reflecting a $60.3 million private placement and an upfront license payment from Chugai [12][13] - Contract revenue for Q4 2025 was $1.5 million, with total revenue for the year at $1.6 million, compared to $1 million for the same period in 2024 [14][15] - Net losses for Q4 2025 were $9.1 million, down from $15.7 million in Q4 2024, while full-year net losses were $41 million compared to $56.6 million in 2024 [16][17] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $4.9 million, down from $6.8 million in Q4 2024, reflecting cost containment measures [15][16] - General and administrative expenses decreased to $5.1 million in Q4 2025 from $5.5 million in Q4 2024, primarily due to reductions in employee compensation [16] Market Data and Key Metrics Changes - The collaboration with Chugai Pharmaceutical has a potential total value of approximately $1.1 billion, highlighting the scalability of the RaniPill platform across multiple therapeutic areas [6][7] - The RaniPill platform aims to transform the delivery of biologics, particularly in the obesity treatment landscape, where current therapies face tolerability challenges [8][11] Company Strategy and Development Direction - The company is focused on advancing the RaniPill platform for oral delivery of biologics, with significant progress in partnerships and pipeline development [4][11] - The strategic partnership with Chugai is expected to enhance the company's capabilities in rare diseases and immunology, with options for expanding the collaboration to additional drug targets [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of the RaniPill platform to improve patient experience in biologic therapies, particularly in obesity treatments [11][18] - The company is well-capitalized to execute its development plans and advance its clinical pipeline, with a projected cash runway extending into Q4 2027 [13][18] Other Important Information - The company has initiated a phase I clinical trial for RT-114, which is expected to provide valuable data on safety, tolerability, and weight loss compared to existing therapies [10][28] - The RaniPill platform has shown promising preclinical data, with RT-114 achieving 111% relative bioavailability compared to subcutaneous PG-102 [8][9] Q&A Session Summary Question: Will weight loss data be presented for RT-114? - Management confirmed that weight loss is one of the endpoints in the phase I-B study, and they will compare it to historical data for PG-102 [20][21] Question: What additional doses will be explored for RT-114? - Management indicated that they are focused on tolerability and may consider exploring higher doses if the data supports it [21][22] Question: What additional value is expected from the phase I study for RT-114? - Management highlighted that the phase I study is the first pharmacodynamics study with the RaniPill in humans, which could unlock broader applicability for the platform [27][28]

Financial Data and Key Metrics Changes - The company reported record quarterly revenue of $25 million in Q4 2025, marking 8 consecutive quarters of year-over-year growth, with annual revenue reaching $92 million in 2025 compared to $86 million in 2024 [4][10] - Gross profit increased to $28 million in 2025 from $25 million in 2024, representing a 13% increase, while gross margin improved to 30% from 28% [5][10] - Operating cash used decreased to $13 million in 2025 from $18 million in 2024, indicating a 27% reduction in cash used in operating activities [5] Business Line Data and Key Metrics Changes - The company launched the advanced SkyFan & Turbo Heater on its e-commerce platform and with major retailers, indicating a focus on expanding product offerings [6] - The Turbo Heater Fan is expected to create a new category of all-season ceiling fans, with plans to introduce larger sizes and new designs based on customer feedback [7][11] Market Data and Key Metrics Changes - The company anticipates deploying over 1 million units of its advanced smart home technologies in various projects across the U.S. and globally, including significant projects in New York, Texas, and Saudi Arabia [8][35] - The company aims to penetrate the market further by deploying over 100,000 products into homes and units by the end of 2026 [8] Company Strategy and Development Direction - The company is focused on becoming cash flow positive by expanding its product categories and leveraging collaborations, such as with NVIDIA for smart home projects [5][14] - The introduction of an AI-driven software in 2026 is expected to enhance sales conversion rates by up to 30% [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth despite a slowdown in the lighting and home decor markets, highlighting consistent revenue growth over the past three years [10][13] - The company is confident in its ability to innovate and create new product categories, which are expected to drive future revenue growth [11][12] Other Important Information - The company has raised $29 million in Q1 2026 through investments from fundamental institutions, providing additional funding for growth initiatives [5] - Management emphasized the importance of safety code standardization for their products, which is expected to enhance market adoption and growth [18][20] Q&A Session Summary Question: Can you elaborate on the safety code standardization timeline? - Management provided details on progress with safety code standardization, mentioning key milestones and the involvement of experienced leaders in the field [18][19] Question: What revenue number is needed to achieve cash flow break-even? - Management indicated that achieving cash flow positive is feasible with the launch of new products and higher gross margins, but specific revenue targets were not disclosed [22][24] Question: How sensitive is the hotel market to interest rates? - Management noted that while interest rates may impact financing, the time-saving aspect of their products provides significant labor cost savings, which is a key selling point [25][29] Question: What is the revenue breakdown between smart plug products and traditional lighting fixtures? - Management stated that over 90% of revenue still comes from legacy products, but growth in smart plug products is accelerating [32] Question: Can you provide an update on major construction projects? - Management confirmed around 12 major projects, including a $4 billion smart city project in Miami, with expectations to start supplying products by the end of the year [33][34] Question: What is the timeline for completing the range of smart plug products? - Management indicated that they are close to completing the range, with 80% of the products ready and discussions with insurance companies underway [38][39]

Financial Data and Key Metrics Changes - For Q4 2025, consolidated revenues were $382.7 million, a 61.7% increase from $236.6 million in Q4 2024. Adjusted EBITDA for the same period was $24.5 million, up from $15 million year-over-year [15][4][16] - For the full year 2025, consolidated revenues reached $1.2 billion, with adjusted EBITDA of $67.2 million [4] Business Line Data and Key Metrics Changes - Infrastructure segment revenues increased by 65.7% to $373.9 million in Q4 2025 from $225.7 million in Q4 2024, driven by increased project activity [16][15] - Life Sciences segment revenues decreased by 24.4% to $3.1 million in Q4 2025 from $4.1 million in Q4 2024, primarily due to lower unit sales in North America [18] - Spectrum segment revenues decreased by $1.1 million to $5.7 million in Q4 2025, with adjusted EBITDA down $1.3 million to $1 million [19] Market Data and Key Metrics Changes - DBM Global's adjusted backlog increased by approximately $700 million to just over $1.8 billion since the end of 2024, reflecting improving demand across markets [5][18] - R2 reported a record revenue of $12.5 million for the full year 2025, representing a 28% year-over-year increase, with international demand surging by 123% [10][11] Company Strategy and Development Direction - The company is focused on strengthening its backlog and advancing strategic initiatives while maintaining financial discipline [4] - MediBeacon's FDA approval for the next generation TGFR system positions it well for commercialization and expansion in 2026 [7][9] - Spectrum is pursuing new network launches and optimizing software and service delivery in collaboration with a mobile wireless carrier [13][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged mixed market conditions but expressed confidence in the company's progress and backlog strength for continued growth in 2026 [4][6] - The company is actively working to address its capital structure and protect shareholder value through asset sales and refinancing efforts [14][20] Other Important Information - As of December 31, 2025, the company had $112.1 million in cash and cash equivalents, a significant increase from $48.8 million at the end of 2024 [19] - The principal outstanding indebtedness was $687.2 million, up $18.9 million from the previous year, influenced by refinancing transactions [20] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded with management expressing gratitude for participants' time and support [21][22]

Financial Data and Key Metrics Changes - Full year net sales nearly doubled to $616.1 million, representing an increase of 89.8% year-over-year from $16.1 million in fiscal 2024 [2][7] - Gross margins improved significantly by 2,800 basis points, rising from 11% in fiscal 2024 to 28% in fiscal 2025 [2][15] - The net operating loss was noted, but cash use for operations did not grow at the same rate as net sales [2][3] Business Line Data and Key Metrics Changes - The hard tonneau covers segment generated $15.7 million in net sales, while the soft cover segment contributed $500,000 [13] - Online retailer net sales increased by 142% to $11.9 million, representing 74% of total net sales in 2025, compared to 58% in 2024 [16] - No private label sales occurred in fiscal 2025, contrasting with $3.1 million or 37% of net sales in fiscal 2024 [16] Market Data and Key Metrics Changes - U.S. net sales were $16 million, up 91% from fiscal 2024, indicating a strong domestic market presence [20] - The dealer network expanded six-fold in fiscal 2025, now encompassing over 550 locations across the U.S. and Canada [9][28] - The company is targeting aggressive expansion into international markets in fiscal 2026 [9][30] Company Strategy and Development Direction - The company aims to capture more market share from large competitors and is focused on lean operations and generating positive operating cash flows [3][10] - Plans for fiscal 2026 include launching a next-generation cover and expanding the dealer network to 1,500 locations [30][40] - The company is pursuing OEM relationships with major automotive manufacturers, including Ford and General Motors [30][59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving operational cash flow positivity in the second half of 2026, driven by margin expansion and new product contributions [26][41] - The macroeconomic environment, including tariffs and supply chain risks, remains a concern, particularly with rising aluminum prices impacting margins [36][50] - The company is focused on maintaining a strong cash position and managing operational expenses effectively [25][42] Other Important Information - The company raised approximately $0.5 million through an At-The-Market offering in 2025 and amended its agreement to allow for additional sales [11] - The company holds 24 issued utility patents and 50 issued design patents globally, with ongoing efforts to protect its intellectual property [37][38] Q&A Session Questions and Answers Question: How should we think about the difference between the high end and the low end of the revenue guide? - Management indicated that market demand, fuel prices, and consumer behavior will significantly influence revenue outcomes [48][50] Question: How do you envision the monetization of the heat pump business? - Management is exploring various options, including manufacturing, marketing, and potential licensing or divestiture of the technology [51][52] Question: Will sales and marketing expenses continue to rise in 2026? - Management plans to tighten marketing expenses after front-loading costs in 2025 [53] Question: Are there any new relationships with truck lines? - Management confirmed ongoing discussions with major automakers and indicated that material relationships would be announced as they develop [59] Question: Can you comment on the sales forecast for SOLIS and COR? - Initial sales have been strong, but marketing assets were only recently released, leading to a delay in ramping up sales [61][62] Question: What is the strength of the intellectual property regarding AetherLux? - Management believes the intellectual property is defensible and unique, with no known competitors offering similar technology [64]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated $46 million in revenue on 328 units delivered, marking the highest number of units delivered in its history [5] - The GAAP gross margin was 5.9%, representing the second consecutive year of positive gross margins [5][29] - The full year operating loss narrowed by 28% to $33.1 million, the lowest since going public, while adjusted EBITDA loss improved by 33% to $23.5 million [6][32] - Positive free cash flow of $5.4 million was generated for the year, a significant improvement from -$49.1 million in 2024 [6][36] Business Line Data and Key Metrics Changes - The fourth quarter revenue was $5.2 million on 34 units, down from $16.5 million on 130 units in the previous quarter, reflecting a seasonal slowdown and a shift in focus to powertrain and hub production [26] - The powertrain business had a breakout year, with 15 powertrain systems delivered to Blue Bird Corporation in Q4 alone, and nearly 100 additional orders received since Q2 [11][12] - The hub product line is expanding, with new configurations being developed to address various customer needs, including energy storage capacities [13][41] Market Data and Key Metrics Changes - The company reported strong demand from national fleets, with significant orders from UPS and FedEx ISPs, indicating a growing confidence in the company's engineering and delivery capabilities [9][10] - The company is addressing grid constraints in North America, which are a major friction point in fleet electrification, through its Hub product line [12][13] Company Strategy and Development Direction - The company aims to accelerate growth, reinforce liquidity, and continue expanding margins in 2026, building on the foundation established in 2025 [38] - The strategy includes diversifying the product portfolio and expanding into higher-margin, less competitive categories [11][12] - The company is positioning itself as an energy company, not just an electric vehicle manufacturer, by expanding its Hub product line to serve various industrial applications [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth and manage costs despite a tumultuous economic environment [5][6] - The company anticipates revenue for 2026 to fall within the range of $40 million to $50 million, with unit deliveries expected to be between 350 and 500 [37] - Management highlighted the importance of maintaining transparency with customers regarding tariff impacts and pricing strategies [72] Other Important Information - The company ended the year with $14 million in cash, up from $11 million, while also paying down obligations and investing in growth [33] - Accounts receivable decreased significantly from $26.9 million to $6 million, driven by strong collections [11][33] Q&A Session Summary Question: Can you talk about the opportunities for the new hub products outside of typical EV charging? - Management discussed various use cases for the hub products, including remote power applications and disaster preparedness, highlighting their versatility [41][42] Question: How do new designs for powertrain products expand opportunities? - Management explained that learnings from deploying vehicles are being applied to new powertrain designs, enhancing reliability and cost competitiveness [48][49] Question: What is the expected unit mix for 2026? - Management indicated a shift towards more powertrains and hubs, with high double-digit growth anticipated for these segments [66][67] Question: Can you provide an update on the UPS program? - Management confirmed that the majority of units for the UPS program have shipped, with only a few remaining to meet revenue recognition criteria [73] Question: Is there potential for retrofitting installed vehicles with V2G capability? - Management stated that retrofitting is technically feasible for later generation vehicles, but commercialization is still under evaluation [83]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $27 million, slightly down from $28 million in Q4 2024, while full-year revenues decreased to $103.5 million from $124 million in 2024 [18][11] - Adjusted operating expenses for Q4 were approximately $17.1 million, a 32% reduction from the beginning of 2025, and a total annualized reduction of $39 million year-over-year, representing a 36% decrease [8][23] - GAAP gross margin in Q4 was 15.8%, impacted by $5.9 million in non-cash inventory adjustments, while adjusted gross margin improved to 37.8% from 34.5% in Q3 2025 [12][21] Business Line Data and Key Metrics Changes - Service revenues in Q4 reached $14.7 million, up 62% year-over-year, representing 54% of total revenue, compared to 32% in Q4 of the previous year [9][19] - Product revenues for Q4 were $11 million, down from $17.2 million in Q4 2024, reflecting a strategic focus on higher-margin opportunities [18][19] Market Data and Key Metrics Changes - Charging service revenue grew 49% year-over-year to $9.3 million, driven by the expanding Blink-owned charging network and strong performance in European markets [13][14] - Network fees for the full year 2025 grew 53% year-over-year to $12.2 million, attributed to an increase in chargers added across the network, particularly DC chargers [14] Company Strategy and Development Direction - The Blink Forward initiative has been pivotal in transitioning the company towards profitability, focusing on contract manufacturing, reducing operating expenses, and enhancing revenue quality [4][7] - The company aims to build a durable, profitable business by expanding its DC fast charging network and increasing repeatable service revenues [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a significantly lower adjusted EBITDA loss in 2026, with a focus on operational excellence and disciplined expense management [66][30] - The company anticipates total revenue for fiscal year 2026 to be in the range of $105 million to $150 million, driven by service revenue growth and strategic product sales [26][27] Other Important Information - The company successfully raised $20 million in December 2025 to fund its DC fast charging investment program, enhancing its financial position [10][26] - Cash burn for Q4 was approximately $2 million, consistent with Q3, indicating strong cash management and operational discipline [17][26] Q&A Session Summary Question: Impact of restructuring on profitability - Management highlighted that the transition to contract manufacturing has reduced inventory risk and improved cash flow, allowing for a more efficient operating model [36][42][45] Question: Gross margin outlook - Management discussed ongoing operational optimizations that could lead to meaningful margin expansion, focusing on reducing costs associated with warranties, shipping, and payment processing [46][54][66] Question: Revenue guidance for 2026 - Management indicated that revenue growth would be influenced by market activity in EV sales, successful installation of DC fast charging projects, and potential market consolidation [68][70] Question: Competitive landscape and M&A opportunities - Management remains open to small M&A opportunities but emphasized a focus on operational execution and maintaining the company's asset-light structure [72][74] Question: Areas of growth for 2026 and beyond - Management indicated a focus on optimizing the existing network and increasing service revenues from the installed base, while also considering strategic M&A in the future [80][82]